Novacyt Earnings Call Balances Progress With Cash Strain

Novacyt S.A. ((FR:ALNOV)) has held its Q4 earnings call. Read on for the main highlights of the call.

Novacyt’s latest earnings call struck a cautiously constructive tone, blending evidence of operational progress with lingering financial strain. Management highlighted modest revenue growth, margin resilience and tighter cost control, as well as an earnings-accretive acquisition and regulatory wins, but also flagged sizeable impairments, shrinking cash reserves and the continued challenge of reaching sustainable profitability.

Revenue Growth Outpaces Expectations

Novacyt reported group revenue of £20.0m for FY2025, modestly ahead of market expectations and up around £0.8m year on year once the Taiwanese divestment is excluded. That translates into roughly 4% organic growth, a small but important step for a business trying to demonstrate it can expand beyond its legacy COVID‑era base.

Robust Gross Margin Underpins Profitability Ambitions

Gross profit climbed to £12.6m, supported by a strong blended gross margin of 63% that reflects the mix of high‑margin PCR and research‑use‑only products. Management highlighted Primer Design’s contribution, with gross margins above 80%, underscoring the value of this portfolio as a profit engine even while absolute sales remain modest.

Operating Costs Trimmed Despite Integration Work

Underlying operating expenditure for the combined Yourgene and Novacyt business fell from roughly £27.5m to £20.4m on a pro forma basis, showing clear progress on integration and efficiency. After stripping out prior‑year bad debt distortions, comparable underlying OpEx still declined about 4%, or £0.7m, indicating tighter cost discipline.

Losses Narrow, But Bottom Line Still Deep in Red

The EBITDA loss improved by around 14% to £7.8m, reflecting the better gross profit and lower operating costs. Loss after tax attributable to shareholders narrowed dramatically to £22.9m from £42.0m, a roughly 45% improvement that nonetheless leaves the company firmly loss‑making.

Instrument Sales and Pipeline Drive Product Momentum

The LightBench Discover launch was a bright spot, helping push instrumentation revenue up around 25% to £2.5m and management cited 20%‑plus instrument growth overall. The imminent launch of the DPYD assay, first as a research‑use‑only product and then as an IVDR‑certified test, is expected to broaden the menu and deepen customer engagement.

Clinical Franchise Strengthened by NIPT and Asia Pac

Clinical testing is increasingly central, contributing about 70% of group revenue or roughly £14m, with non‑invasive prenatal testing alone growing around 10% to about £5m. New contracts such as St. George’s University Hospital and a win in Iceland, alongside double‑digit expansion in Asia Pacific where revenue is about 30% of the group total, underline the geographic and segment diversification.

Southern Cross Deal Adds Scale and Earnings Accretion

The acquisition of Southern Cross Diagnostics, bought for an upfront consideration of around $8.5m with potential earn‑outs over four years, has quickly become a strategic pillar. The business generates more than £6m of revenue and has tripled since 2023, and management said integration is roughly 75% complete even though only about 60% of the planned timeline has elapsed.

IVDR Approvals Build a Regulatory Moat

Novacyt secured IVDR accreditation for its QST*R‑based assay, which management framed as a competitive advantage in a tightening regulatory landscape. They argued that as IVDR requirements bite over the next 12 to 24 months, some rivals may struggle, potentially reducing competitive intensity and supporting pricing and market share.

Heavy Exceptional Charges Mask Underlying Progress

Results were overshadowed by nearly £16m of exceptional charges in FY2025, dominated by a non‑cash impairment of about £14.4m tied to goodwill and intangibles from the Yourgene acquisition. That write‑down materially reduced non‑current assets and serves as an acknowledgment that prior deal valuations will not be fully recovered.

Cash Erosion Raises Near‑Term Liquidity Questions

Cash dropped by roughly £11m during FY2025 to £19m at year‑end and fell further to about £11m by end‑March 2026 after first‑quarter outflows of around £8m. While about £5m of that Q1 outflow related to the Southern Cross purchase, an average monthly cash burn of roughly £825k underlines the pressure to accelerate growth and curtail losses.

Ongoing Operating Losses Keep Profitability Elusive

Despite the steps forward on revenue, margins and costs, Novacyt remains some distance from breakeven, with an FY2025 EBITDA loss of £7.8m and a post‑tax loss of £22.9m. Management reiterated the path to profitability, but investors will want to see a faster conversion of the stronger top line into consistent positive earnings.

Earn‑Out Targets Create Additional Execution Risk

The Southern Cross deal carries a sizeable contingent consideration linked to cumulative EBITDA above AUD 30m over four years to unlock the full deferred payment. This structure aligns incentives toward growth but also introduces future performance and cash obligations that will matter if market conditions soften or integration stumbles.

Regulatory and Product Hurdles Temper the Growth Story

Not all product news was positive, as the company’s SMA test encountered regulatory questions during OEM approval, prompting a pause and reassessment of the development route. That delay injects uncertainty into the timing and profitability of a potentially attractive launch and illustrates the regulatory complexity of expanding the test menu.

Margin Risk in Value‑Conscious Markets

Management acknowledged that some Asia Pacific markets, while growing quickly, are highly price‑sensitive and could drag on overall margins as they scale. Balancing volume gains in these regions with the need to protect the group’s attractive gross margin will be an important lever for sustaining earnings quality.

Geopolitics and Supply Chain Disruption on the Radar

The conflict in the Middle East has forced the company to reroute some supply paths, leading to modest delays in lead times so far, though no major financial impact has been seen. Nonetheless, management highlighted this as an ongoing operational risk that could worsen if geopolitical tensions escalate or logistics bottlenecks deepen.

Battling Weak Market Sentiment

Executives were candid about the low share price and limited visibility among both retail and institutional investors, which could constrain future funding options. They plan to step up communication efforts to better explain the strategy and progress, but sentiment remains a headwind until the financial trajectory improves more decisively.

Guidance and Push Toward EBITDA Break‑Even

Looking ahead, management is targeting double‑digit revenue growth for 2026, with external forecasts pointing to about £26.4m of sales, and reiterated their ambition to reach EBITDA profitability. They believe existing funds can last into April 2027 if forecasts are met, with the growth of clinical, RUO and instrumentation lines and the contribution from Southern Cross all expected to drive the transition toward positive earnings.

Novacyt’s earnings call painted a picture of a company moving in the right strategic and operational direction but still wrestling with meaningful financial and execution risk. Investors will be watching closely to see whether rising clinical volumes, product launches and the Southern Cross deal translate into sustained growth, improved cash generation and, ultimately, a durable path to profitability.